European consortium to validate blood-based biomarkers for cancer

Alacris is one of the partners of CANCER-ID, a newly formed European consortium funded by the Innovative Medicines Initiative (IMI). CANCER-ID consists of currently 33 partners from 13 countries aiming at the establishment of standard protocols for and clinical validation of blood-based biomarkers. The consortium brings together experts from academic and clinical research, innovative Small-to-Medium sized Enterprises (SMEs) such as Alacris Theranostics, diagnostics companies and the pharmaceutical industry thus providing a unique setting for establishing clinical utility of “liquid biopsies”.